MiMedx Group, Inc. has raised $150m in private equity and debt financing to scale commercialization of its advanced wound care products, marking a vote of confidence in the company’s new C-suite team.
MiMedx’s core business develops amniotic tissue products. The company uses a manufacturing process to transform human placental tissue into a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?